Patents by Inventor Weiduan Xu
Weiduan Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7566546Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.Type: GrantFiled: February 16, 2005Date of Patent: July 28, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: James Lorens, Sacha J. Holland, Weiduan Xu
-
Patent number: 7527936Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.Type: GrantFiled: January 13, 2005Date of Patent: May 5, 2009Assignee: Rigel Pharmaceuticals Inc.Inventors: Weiduan Xu, Sacha J. Holland, James Lorens
-
Patent number: 7485414Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.Type: GrantFiled: August 30, 2002Date of Patent: February 3, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
-
Patent number: 7419779Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.Type: GrantFiled: September 2, 2003Date of Patent: September 2, 2008Assignee: Rigel Pharmaceuticals, Inc.Inventors: James B. Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
-
Patent number: 7244576Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.Type: GrantFiled: August 21, 2001Date of Patent: July 17, 2007Assignee: Rigel Pharmaceuticals, Inc.Inventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger
-
Publication number: 20060264392Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic adds, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.Type: ApplicationFiled: September 2, 2003Publication date: November 23, 2006Inventors: James Lorens, Jakob Bogenberger, Sacha Holland, Weiduan Xu
-
Publication number: 20050250163Abstract: The present invention relates to regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of endothelial cell haptotaxis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.Type: ApplicationFiled: February 16, 2005Publication date: November 10, 2005Applicant: Rigel Pharmaceuticals, IncorporatedInventors: James Lorens, Sacha Holland, Weiduan Xu
-
Publication number: 20050208472Abstract: The present invention relates to regulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis and cancer.Type: ApplicationFiled: January 13, 2005Publication date: September 22, 2005Applicant: Rigel Pharmaceuticals, IncorporatedInventors: Weiduan Xu, Sacha Holland, James Lorens
-
Publication number: 20040053233Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of angiogenesis regulatory proteins and nucleic acids; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.Type: ApplicationFiled: August 30, 2002Publication date: March 18, 2004Applicant: Rigel Pharmaceuticals, IncorporatedInventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger, Sacha Holland
-
Publication number: 20030176333Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding contactin associated protein 3 (CASPR3), which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, RNAi, and ribozymes, that modulate angiogenesis via modulation of CASPR3; as well as to the use of expression profiles and compositions in diagnosis and therapy of diseases related to angiogenesis.Type: ApplicationFiled: March 18, 2002Publication date: September 18, 2003Applicant: Rigel Pharmaceuticals, IncorporatedInventors: James B. Lorens, Weiduan Xu, Jakob Bogenberger
-
Publication number: 20020156003Abstract: The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding C1-angiogenesis protein, also called integrin-linked kinase associated protein (“ILKAP”) and ILKAP protein, which is involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate angiogenesis via modulation of ILKAP and ILKAP-related cascades; as well as to the use of expression profiles and compositions in diagnosis and therapy of angiogenesis.Type: ApplicationFiled: August 21, 2001Publication date: October 24, 2002Applicant: Rigel Pharmaceuticals, IncorporatedInventors: James B. Lorens, Weiduan Xu, Robert E. Atchison, Jakob Bogenberger